IRNF App vs Tempus ECG-AF
AI Verdict
Choose IRNF App if…
Choose the IRNF App if you are an individual seeking a convenient, over-the-counter solution for continuous, passive monitoring of irregular heart rhythms suggestive of Atrial Fibrillation (AFib) through your Apple Watch. This tool is ideal for proactive self-monitoring and receiving notifications directly on your mobile device, integrating seamlessly with your personal health data.
View IRNF App →Choose Tempus ECG-AF if…
Choose Tempus ECG-AF if you are a healthcare provider looking to clinically assess patients aged 65 or older for their risk of developing new-onset Atrial Fibrillation within the next 12 months. This AI-based algorithm integrates into healthcare facility systems to analyze 12-lead ECGs, providing valuable risk stratification to guide further diagnostic workup and preventative care within a medical setting.
View Tempus ECG-AF →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | IRNF App | Tempus ECG-AF |
|---|---|---|
| Pricing | Free | Contact vendor |
| Deployment | Mobile (iOS, watchOS) | Software solution, integrated into healthcare facility systems with advanced cardiology algorithms. |
| BAA Available | No AI-estimated | Yes AI-estimated |
| FDA Status | 1 AI-estimated | Yes AI-estimated |
| HIPAA | Unknown | Yes AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
IRNF AppTool A, the IRNF App, is designed for direct consumer use on personal mobile devices like the Apple Watch and iPhone, offering intuitive integration with Apple Health and educational materials. Tool B, Tempus ECG-AF, is integrated into healthcare facility systems, requiring professional operation within a clinical workflow. Therefore, Tool A is significantly more accessible and user-friendly for the general public.
Clinical Value
Tempus ECG-AFTool A provides real-time detection of irregular rhythms suggestive of AFib, empowering individuals to seek timely medical attention. Tool B offers a predictive risk assessment for new-onset AFib within 12 months for a high-risk population (65+), enabling proactive clinical management and earlier intervention. Tool B's ability to predict future risk using a standard diagnostic allows for more impactful preventative strategies within a healthcare system.
Pricing & Value
IRNF AppTool A is a free feature included with compatible Apple Watch and iPhone models, offering immense value at no additional cost to the end-user. Tool B is a paid service with specific CMS reimbursement available, representing a cost to the healthcare provider or system. Tool A's free availability provides unparalleled value and accessibility.
Enterprise Readiness
Tempus ECG-AFTool A is a consumer mobile application with no stated Business Associate Agreement (BAA) or enterprise integration features. Tool B explicitly states HIPAA compliance and a BAA, and is designed for integration into healthcare facility systems. Tool B is purpose-built for enterprise deployment within healthcare, adhering to critical compliance standards.
Innovation
TieTool A innovates by democratizing FDA-cleared AFib detection through a widely adopted consumer wearable, making health monitoring accessible to a broad population. Tool B innovates by applying AI to standard 12-lead ECGs to predict future AFib risk in a specific demographic, enabling novel proactive clinical strategies. Both represent significant innovation in their respective domains.
Support & Docs
IRNF AppTool A, as an Apple product, benefits from Apple's extensive user support infrastructure, readily available online documentation, and in-app educational materials. Tool B, as an enterprise solution, would have vendor-specific support channels for healthcare facilities, but public documentation and direct user support details are not specified. Tool A likely offers superior and more accessible support for its target users.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | IRNF App | Tempus ECG-AF |
|---|---|---|
| Name | IRNF App | Tempus ECG-AF |
| Company | Apple | Tempus AI, Inc. |
| Target Population/Use Case | Detects irregular heart rhythms suggestive of Atrial Fibrillation (AFib) and notifies users; Over-the-counter (OTC) use. | Identify patients aged 65 or older at increased risk of developing atrial fibrillation/flutter (AF) within the next 12 months, supporting earlier identification and follow-up; Intended for patients 65 years or older without pre-existing AF, pacemakers, ICDs, or recent cardiac surgery. |
| Input Data | Pulse rate data analysis using Apple Watch PPG sensor | 12-lead ECG recordings (compatible with FDA authorized resting 12-lead ECGs from GE Medical Systems and Philips Medical Systems) |
| Detection Mechanism | Irregular heart rhythm detection; Utilizes machine learning for rhythm classification. | AI-based algorithm that analyzes 12-lead ECG recordings. |
| Specialties | Cardiology, Internal Medicine | Cardiology, Geriatrics, Internal Medicine |
Videos
Demos, reviews, and walkthroughs featuring IRNF App and Tempus ECG-AF.
Frequently Asked Questions
More Comparisons
More matchups featuring IRNF App or Tempus ECG-AF
Backers
Who funded each tool's parent company.